Alemtuzumab and Fatal Myocarditis

Affiliations

¹ Burden Professor of Clinical Neurosciences (NJS), University of Bristol and Southmead Hospital, Bristol, United Kingdom; Consultant Pathologist (HA), United Kingdom; Professor of Cardiovascular Pathology (MS), Department of Cardiovascular Pathology, St George's Medical School, University of London, United Kingdom; and Director of Transplant and Consultant Cardiac Surgeon (ARS), Royal Brompton and Harefield NHS Foundation Trust, Harefield Hospital, Harefield, Middlesex, United Kingdom.

Case Reports

Neil J Scolding et al. Neurol Clin Pract. 2021 Feb.

. 2021 Feb;11(1):e46-e47.

doi: 10.1212/CPJ.0000000000000772.

¹ Burden Professor of Clinical Neurosciences (NJS), University of Bristol and Southmead Hospital, Bristol, United Kingdom; Consultant Pathologist (HA), United Kingdom; Professor of Cardiovascular Pathology (MS), Department of Cardiovascular Pathology, St George's Medical School, University of London, United Kingdom; and Director of Transplant and Consultant Cardiac Surgeon (ARS), Royal Brompton and Harefield NHS Foundation Trust, Harefield Hospital, Harefield, Middlesex, United Kingdom.

No abstract available

Figures

1. Katsavos S, Coles A. Alemtuzumab as treatment for multiple sclerosis. Cold Spring Harb Perspect Med 2018;8:a032029. - PMC - PubMed
1. Reuben A, Petaccia de Macedo M, McQuade J, et al. . Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab. Oncoimmunology 2017;6:e1361097. - PMC - PubMed
1. Raikhelkar J, Uriel N. Immune checkpoint inhibitor myocarditis. Curr Opin Cardiol 2019;34:303–306. - PubMed
1. Evans JD, Pettit SJ, Goddard M, Lewis C, Parameshwar JK. Alemtuzumab as a novel treatment for refractory giant cell myocarditis after heart transplantation. J Heart Lung Transplant 2016;35:256–258. - PubMed
1. Esfahani K, Buhlaiga N, Thébault P, Lapointe R, Johnson NA, Miller WH Jr. Alemtuzumab for immune-related myocarditis due to PD-1 therapy. New Engl Journal Medicine 2019;380:2375–2376. - PubMed